BG
AURA icon

Bellevue Group’s Aura Biosciences AURA Stock Holding History

Bellevue Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.28M Buy
+1,166,667
New +$8.35M 0.17% 73

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bellevue Group's AURA Position: Q2 2026 in Review

Bellevue Group opened a new position in Aura Biosciences (AURA) in Q2 2026: 1,166,667 shares worth $8.28M. The stake represents 0.17% of the portfolio and ranks #73 among its holdings.

118 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Bellevue Group held 1,166,667 shares of Aura Biosciences worth $8.28M as of Q2 2026.
  • Aura Biosciences was a new Bellevue Group position in Q2 2026.
  • Aura Biosciences made up 0.17% of Bellevue Group's portfolio in Q2 2026, its #73 holding.
  • 118 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.